Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
Public ClinicalTrials.gov record NCT05134974. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Parallel Arm, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Healthy Subjects
Study identification
- NCT ID
- NCT05134974
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Ocuphire Pharma, Inc.
- Industry
- Enrollment
- 368 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 17, 2021
- Primary completion
- Mar 17, 2022
- Completion
- Mar 28, 2022
- Last update posted
- Aug 28, 2023
2021 – 2022
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Site 10 | Newport Beach | California | 92663 | — |
| Clinical Site 12 | Westminster | California | 92655 | — |
| Clinical Site 9 | Delray Beach | Florida | 33484 | — |
| Clinical Site 8 | Longwood | Florida | 32779 | — |
| Clinical Site 6 | Morrow | Georgia | 30260 | — |
| Clinical Site 1 | Roswell | Georgia | 30009 | — |
| Clinical Site 13 | Lake Villa | Illinois | 60046 | — |
| Clinical Site 5 | Pittsburg | Kansas | 66762 | — |
| Clinical Site 2 | Bloomington | Minnesota | 55420 | — |
| Clinical Site 15 | Garner | North Carolina | 27529 | — |
| Clinical Site 4 | Athens | Ohio | 45701 | — |
| Clinical Site 14 | Shrewsbury | Pennsylvania | 17349 | — |
| Clinical Site 7 | Warwick | Rhode Island | 02888 | — |
| Clinical Site 11 | Sioux Falls | South Dakota | 57101 | — |
| Clinical Site 3 | Memphis | Tennessee | 38119 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05134974, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2023 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05134974 live on ClinicalTrials.gov.